UNIVASC
LOE ApproachingNDAORALTABLET
Approved
Apr 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UNIVASC (moexipril hydrochloride) is an oral ACE inhibitor approved in 1995 for hypertension management. It is a prodrug that converts to moexiprilat, which inhibits angiotensin-converting enzyme (ACE) to reduce vasoconstriction and lower blood pressure. The drug works by blocking the renin-angiotensin-aldosterone system, with demonstrated efficacy primarily in non-black populations.
LOE Approaching
Product is nearing loss of exclusivity with moderate competitive pressure (score: 30/100), indicating a consolidating team focused on generic transition planning and lifecycle extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on UNIVASC offers limited growth opportunity given its LOE-approaching status and zero linked job openings, making it a defensive career assignment focused on margin protection and generic transition management. Career advancement on this product is constrained; professionals should expect focus on cost-effectiveness, payer relationships, and managed decline rather than expansion or innovation.
Brand Manager
Worked on UNIVASC at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.